Low-dose conbercept for retinopathy of prematurity
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether a low dose of conbercept, given as an eye injection, can safely treat type 1 ROP (an eye disease in premature babies). The goal is to stop abnormal blood vessel growth and prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born prematurely, weighing at most 2000 grams (4 lb 6 oz) or before 32 weeks of pregnancy.
- Your baby has a specific form of ROP (type 1) in both eyes, as confirmed by an eye exam.
- Your baby has not received any prior ROP treatment such as laser, anti-VEGF injections, or eye surgery.
- Your baby (or you, during pregnancy) has not received any anti-VEGF medication before.
- Your baby does not have an active eye infection or any other medical condition that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the tiny blood vessels in the back of the eye (retina) of premature infants who are at risk for retinopathy of prematurity, a condition that can harm vision. It aims to improve care and monitoring by using advanced eye imaging to see more detail than current methods.
This study looks at children who had ROP (an eye problem in premature babies) to see how their vision and the back of the eye (retina) develop over time. It compares children who received treatment with those who did not, to learn more about long-term effects.
This study tests a new eye imaging device to check for retinopathy of prematurity (ROP), a condition that can affect vision in premature babies. It may help doctors diagnose ROP earlier and more easily at the bedside.
This study tests two drug-free methods to help reduce pain when premature babies get a special eye exam for retinopathy of prematurity. It may help your baby feel more comfortable during the procedure.
This study tests a new medicine called FLQ-101 in very premature babies born between 25 and 27 weeks of pregnancy. The goal is to see if the medicine is safe and how it works in the body.
This trial tests whether giving propranolol by mouth to certain very premature babies with early eye changes can stop retinopathy of prematurity from getting worse. It may help reduce the need for eye treatments later on.
Hear when a new Retinopathy of Prematurity (ROP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.